Patent: 10,081,671
✉ Email this page to a colleague
Summary for Patent: 10,081,671
| Title: | Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV) |
| Abstract: | This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1.times.10.sup.-9M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein. |
| Inventor(s): | Koch; Holger (San Jose, CA), Urwyler; Simon (San Jose, CA), Rudolf; Michael (San Jose, CA), Truong; Vu (Campbell, CA) |
| Assignee: | |
| Application Number: | 15/523,190 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,081,671
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2039-02-26 |
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
